Ultragenyx Pharmaceutical Inc.RARENASDAQ

Revenue (LTM)

$673M

+20.1% YoY

Net Income (LTM)

$-575M

-1.0% YoY

Free Cash Flow

$-472M

Revenue CAGR (5Y)

+19.9%

Marginsdeclining

FCF($0.5B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	351	363↑3.4%	434↑19.5%	560↑29.0%	673↑20.1%
Gross Profit	335	335↓0.1%	389↑16.1%	484↑24.3%	564↑16.6%
Operating Income	-382	-649↓70.0%	-569↑12.3%	-536↑5.8%	-535↑0.2%
Net Income	-454	-707↓55.8%	-607↑14.2%	-569↑6.2%	-575↓1.0%
EBITDA	-410	-640↓56.1%	-516↑19.4%	-469↑9.2%	-500↓6.6%
EPS Diluted	-6.70	-10.12↓51.0%	-8.25↑18.5%	-6.29↑23.8%	-5.83↑7.3%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	308	133↓56.8%	214↑60.7%	174↓18.7%	434↑149.8%
Total Current Assets	857	884↑3.2%	732↓17.2%	817↑11.6%	951↑16.4%
Total Assets	1,522	1,545↑1.5%	1,491↓3.5%	1,503↑0.8%	1,532↑1.9%
Total Current Liabilities	181	261↑44.0%	280↑7.4%	344↑22.7%	384↑11.6%
Total Liabilities	600	1,193↑98.9%	1,216↑1.9%	1,241↑2.1%	1,605↑29.3%
Total Equity	923	352↓61.8%	275↓21.9%	255↓7.3%	-80↓131.3%
Total Debt	42	32↓24.7%	43↑36.6%	40↓6.6%	1,276↑3063.2%
Net Debt	-266	-101↑61.8%	-170↓68.1%	-133↑21.7%	842↑731.2%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-339	-380↓12.3%	-475↓24.8%	-414↑12.8%	-466↓12.5%
Capital Expenditure	-73	-146↓99.9%	-47↑68.0%	-7↑84.0%	-6↑19.9%
Free Cash Flow	-412	-527↓27.9%	-522↑1.0%	-422↑19.2%	-472↓11.9%
Stock-Based Comp	105	130↑24.2%	135↑3.7%	158↑16.9%	153↓3.2%
Net Change in Cash	-417	-172↑58.7%	82↑147.6%	-35↓143.1%	253↑819.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance